Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication
- Authors
- Jung, Y. S.; Kim, E. H.; Park, Chan Hyuk
- Issue Date
- Jul-2017
- Publisher
- WILEY
- Citation
- ALIMENTARY PHARMACOLOGY & THERAPEUTICS, v.46, no.2, pp.106 - 114
- Indexed
- SCIE
SCOPUS
- Journal Title
- ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Volume
- 46
- Number
- 2
- Start Page
- 106
- End Page
- 114
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/4135
- DOI
- 10.1111/apt.14130
- ISSN
- 0269-2813
- Abstract
- Background
In order to increase eradication rates, vonoprazan, a novel potassium-competitive acid blocker, has been used in Helicobacter pylori eradication therapy.
Aim
To summarise the results of the efficacy of vonoprazan-based triple therapy, helping clinicians to better understand the benefit of vonoprazan in the treatment of H. pylori infection.
Methods
We conducted a systematic literature search on MEDLINE, EMBASE, and the Cochrane Library using the primary keywords “vonoprazan,” “takecab”, “TAK-438,” “potassium,” “competitive,” “potassium-competitive,” “Helicobacter,” and “pylori.” Studies were included if they evaluated the eradication rate between the vonoprazan-based and proton pump inhibitor (PPI)-based triple therapies.
Results
Ten studies and 10 644 patients were evaluated. The crude H. pylori eradication rate determined by intention-to-treat analysis was 87.9% and 72.8% in the vonoprazan-based triple therapy and PPI-based triple therapy respectively. The eradication rate of the vonoprazan-based triple therapy was superior to that of the PPI-based triple therapy (pooled risk ratio [RR] [95% confidence interval (CI)]=1.19 [1.15-1.24]) In addition, there was no significant difference in dropout rate due to adverse event between the regimens (pooled RR of the vonoprazan-based triple therapy [95% CI]=0.69 [0.23-2.03]). The incidence of any adverse events also did not differ between the regimens (pooled RR [95% CI]=1.02 [0.78-1.34]).
Conclusions
The vonoprazan-based triple therapy showed superior efficacy in terms of H. pylori eradication as compared to the PPI-based triple therapy. In addition, the vonoprazan-based triple therapy showed comparable tolerability and incidence of adverse events.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/4135)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.